Janux Therapeutics JANX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$114.48M-0.8% | -$113.63M-11.5% | -$101.9M+3.5% | -$105.64M-35.9% | -$77.74M-12.7% | ||
| $1.98M-2.5% | $2.03M-2.1% | $2.07M-0.4% | $2.08M+1.7% | $2.05M-0.6% | ||
| $38.79M-3.6% | $40.22M+8.8% | $36.96M-14.6% | $43.3M+13.7% | $38.1M+15.4% | ||
| —— | —— | —— | —— | —— | ||
| $1M+2.6% | $977K+12.7% | $867K-60.8% | $2.21M+448% | $403K-74.6% | ||
| —— | —— | —— | —— | —— | ||
| $1.15M+517% | -$276K-40.8% | -$196K-470% | $53K-80.2% | $268K-28.5% | ||
| $46.27M— | $0— | $0+100% | -$94K+90.3% | -$972K+43.0% | ||
| -$77.55M+5.7% | -$82.24M-16.8% | -$70.42M-17.8% | -$59.79M-30.0% | -$46M-5.0% | ||
| $945K-9.4% | $1.04M+6.5% | $979K+7.5% | $911K+70.9% | $533K+48.5% | ||
| $446.68M-36.7% | $705.22M+16.4% | $605.98M+16.4% | $520.47M-21.5% | $663.33M+41.0% | ||
| $495.32M+22.2% | $405.28M+30.6% | $310.36M+35.4% | $229.16M+27.9% | $179.19M-15.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $7.94M+60.5% | $4.95M-98.7% | $388.65M-0.3% | $389.81M-0.5% | $391.62M-45.1% | ||
| -$25.86M+93.2% | -$382.22M-1,867% | $21.64M-42.7% | $37.78M+127% | -$139.06M-134% | ||
| $15.98M-9.1% | $17.57M+3.5% | $16.98M+11.3% | $15.25M+17.2% | $13.02M+23.0% | ||
| $1.98M-2.5% | $2.03M-2.1% | $2.07M-0.4% | $2.08M+1.7% | $2.05M-0.6% | ||
| $46.27M— | $0— | $0+100% | -$94K+90.3% | -$972K+43.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $1.4M-50.3% | $2.81M-14.4% | ||
| $495.32M+22.2% | $405.28M+30.6% | $310.36M+35.4% | $229.16M+27.9% | $179.19M-15.8% | ||
| —— | —— | —— | —— | —— | ||
| -$212K— | $0— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $943K+33.3% | $707.25K— | —— | —— | ||
| -$78.49M+5.7% | -$83.28M-16.6% | -$71.4M-17.6% | -$60.7M-30.5% | -$46.53M-5.3% | ||
| -$78.49M+5.7% | -$83.28M-16.6% | -$71.4M-17.6% | -$60.7M-30.5% | -$46.53M-5.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Janux Therapeutics generate?
- Janux Therapeutics (JANX) generated -$77.5M in operating cash flow over the trailing twelve months.
- What is Janux Therapeutics's free cash flow?
- After $945.0K of capital expenditures, Janux Therapeutics's free cash flow was -$78.5M over the trailing twelve months, down 68.7% year over year.
- Where does Janux Therapeutics's cash flow data come from?
- Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
